BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3524832)

  • 21. Review of etoposide.
    Phillips NC; Lauper RD
    Clin Pharm; 1983; 2(2):112-9. PubMed ID: 6309469
    [No Abstract]   [Full Text] [Related]  

  • 22. [Treatment of anaplastic carcinoma of the lung with VP 16-213].
    Sanz Ortíz J; Saiz García F
    Med Clin (Barc); 1982 Oct 16-31; 79(7):322-4. PubMed ID: 6294420
    [No Abstract]   [Full Text] [Related]  

  • 23. [Effect of etoposide for urogenital tumors].
    Kinjo T; Murase T; Aota Y; Shimoji T; Mitsuya H
    Gan To Kagaku Ryoho; 1985 Jun; 12(6):1267-71. PubMed ID: 4004290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [New antineoplastic drugs of the podophyllotoxin derivative group].
    Robak T; Płuzańska A
    Pol Tyg Lek; 1983 Jan; 38(1):27-30. PubMed ID: 6346283
    [No Abstract]   [Full Text] [Related]  

  • 25. [Collaborative phase II study of etoposide (NK-171). Urological Cooperative Study Group of etoposide (NK-171)].
    Gan No Rinsho; 1985 Jul; 31(8):944-52. PubMed ID: 4040986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Etoposide (VP-16-213).
    Issell BF; Crooke ST
    Cancer Treat Rev; 1979 Jun; 6(2):107-24. PubMed ID: 385138
    [No Abstract]   [Full Text] [Related]  

  • 27. Phase II trial of etoposide in previously treated small cell carcinoma of the lung.
    Antman K; Pomfret E; Karp G; Skarin A; Canellos G
    Cancer Treat Rep; 1984 Nov; 68(11):1413-4. PubMed ID: 6094004
    [No Abstract]   [Full Text] [Related]  

  • 28. Etoposide in small cell lung cancer resistant to prior chemotherapy.
    Asbury RF; Rubins J; Bennett JM
    Cancer Treat Rep; 1983 Oct; 67(10):951-2. PubMed ID: 6313187
    [No Abstract]   [Full Text] [Related]  

  • 29. Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update.
    Linker CA; Damon LE; Ries CA; Rugo HS; Wolf JL
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):40-8; quiz 49. PubMed ID: 8342075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
    Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
    Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does etoposide have curative potential?
    Ignoffo RJ
    Clin Pharm; 1983; 2(2):167. PubMed ID: 6309470
    [No Abstract]   [Full Text] [Related]  

  • 32. VP-16-213 therapy in patients with small-cell carcinoma of the lung after failure on combination chemotherapy.
    Tempero M; Kessinger A; Lemon HM
    Cancer Clin Trials; 1981; 4(2):155-7. PubMed ID: 6265110
    [No Abstract]   [Full Text] [Related]  

  • 33. [Phase II study of NK 171 (etoposide) on malignant lymphomas and acute leukemia. A cooperative study group on NK 171 in hematological malignancies].
    Kimura K; Yamada K; Yoshida T
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):496-501. PubMed ID: 3954373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis.
    Chang TT; Gulati SC; Chou TC; Vega R; Gandola L; Ibrahim SM; Yopp J; Colvin M; Clarkson BD
    Cancer Res; 1985 Jun; 45(6):2434-9. PubMed ID: 3857119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autologous bone marrow transplantation in neoplasia.
    Dicke KA; Vellekoop L; Spitzer G; Zander AR; Schell F; Verma DS
    Transplant Proc; 1981 Mar; 13(1 Pt 1):267-9. PubMed ID: 6267751
    [No Abstract]   [Full Text] [Related]  

  • 36. High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study.
    Wolff SN; Fer MF; McKay CM; Hande KR; Hainsworth JD; Greco FA
    J Clin Oncol; 1983 Nov; 1(11):701-5. PubMed ID: 6366131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effects of oral etoposide in small cell carcinoma of the lung].
    Miyamoto H; Ito M; Araya Y; Takaoka K; Isobe H; Dosaka H; Kawakami Y; Shimizu T; Onodera S
    Gan To Kagaku Ryoho; 1984 Jun; 11(6):1244-7. PubMed ID: 6329103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Etoposide by oral route in the treatment of unresectable non-small cell lung cancer.
    Scagliotti G; Lodico D; Gozzelino F; Pescetti G
    Chemioterapia; 1984 Oct; 3(5):324-6. PubMed ID: 6532545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose etoposide in the treatment of relapsed primary brain tumors.
    Finn GP; Bozek T; Souhami RL; Slevin ML; Thomas DG
    Cancer Treat Rep; 1985 Jun; 69(6):603-5. PubMed ID: 4016766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A phase I study of VP-16-213 (VP, etoposide) by single and 5-day intravenous administration].
    Wakui A; Yokoyama M; Takahashi H; Yoshida Y; Sakata Y; Sato S; Kano A; Kawamoto K; Hashimoto S; Konno K
    Gan To Kagaku Ryoho; 1986 Feb; 13(2):319-29. PubMed ID: 3947109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.